Saniona
Saniona publishes its interim report for the first quarter of 2023
MAR
Q1 2023 (2022) |
Revenue was SEK 2.2 M (6.6 M) |
Operating profit/loss was SEK -21.1 M (-133.2 M) |
Net profit/loss was SEK -21.7 M (-133.4 M) |
Basic earnings/loss per share was SEK -0.35 (-2.14) |
Diluted earnings/loss per share were SEK -0.35 (-2.14) |
Business highlights in Q1 2023
- On January 17, Saniona announced successful preclinical in vivo validation for treatment of migraine in the Cephagenix joint venture program.
- On February 25, Saniona announced that its partner Medix received favorable opinion for tesofensine for the treatment of obesity and weight management in Mexico.
Significant events after the reporting period
- There have been no events after the reporting period.
Comments from the CEO
“Good progress on partnering negotiations and a potential approval of tesofensine in Mexico for treatment of obesity.”
Datum | 2023-05-25, kl 08:00 |
Källa | MFN |
